We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

85 hedge funds and large institutions have $605M invested in Protagonist Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more capital invested

Capital invested by funds: $165M → $605M (+$440M)

200% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 14

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

13.81% more ownership

Funds ownership: 85.66% → 99.47% (+14%)

10% more funds holding

Funds holding: 77 → 85 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
85
Holders Change
+8
Holders Change %
+10.39%
% of All Funds
1.74%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
25
Increased
42
Reduced
14
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$27.6M
2
BI
BVF Inc
California
+$21M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.4M
4
DM
Deerfield Management
New York
+$12.7M
5
FCM
Farallon Capital Management
California
+$12.5M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$3.71M
2
Citadel Advisors
Citadel Advisors
Florida
-$3.31M
3
GTC
Ghost Tree Capital
New York
-$1.61M
4
IC
Ikarian Capital
Texas
-$1.12M
5
VA
VR Adviser
New York
-$799K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$3.41M +$1.02M +81,037 +219%
Russell Investments Group
27
Russell Investments Group
United Kingdom
$3.21M +$970K +77,296 +74%
PAM
28
Panagora Asset Management
Massachusetts
$2.66M +$1.32M +105,195 +231%
AG
29
Artal Group
Luxembourg
$2.47M +$1.76M +140,000 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.79M +$223K +17,769 +21%
MAM
31
Martingale Asset Management
Massachusetts
$1.72M +$1.22M +97,200 New
Arrowstreet Capital
32
Arrowstreet Capital
Massachusetts
$1.49M +$1.06M +84,417 New
Allianz Asset Management
33
Allianz Asset Management
Germany
$1.34M -$330K -26,308 -26%
UBS Group
34
UBS Group
Switzerland
$1.21M -$57K -4,546 -6%
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$1.21M -$51.2K -4,078 -6%
Prudential Financial
36
Prudential Financial
New Jersey
$1.19M -$63.2K -5,035 -7%
Citigroup
37
Citigroup
New York
$1.14M +$722K +57,525 +819%
Charles Schwab
38
Charles Schwab
California
$1.01M +$165K +13,168 +30%
Bessemer Group
39
Bessemer Group
New Jersey
$945K +$671K +53,500 New
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$883K +$627K +50,000 New
JGC
41
J. Goldman & Co
New York
$872K +$619K +49,359 New
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$825K +$221K +17,590 +60%
N
43
Nuveen
North Carolina
$701K -$104K -8,301 -8%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$695K +$494K +39,353 New
WG
45
Winton Group
United Kingdom
$682K +$10.4K +828 +2%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$601K +$90.2K +7,188 +27%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$524K +$163K +13,005 +78%
Connor, Clark & Lunn Investment Management (CC&L)
48
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$505K +$359K +28,598 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$494K +$149K +11,900 +74%
FSA
50
Franklin Street Advisors
North Carolina
$411K -$2.51K -200 -0.9%
1
2
3 4 5

PTGX Hedge Fund Activity: Q2 2020 in Review

85 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2020, worth a combined $605M — up 267% from $165M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PTGX positions and 17 closed out — a net gain of 8 holders — while 42 added to existing stakes and 14 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $27.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.71M sold.

  • 85 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2020, up from 77 in Q1 2020.
  • Funds reported $605M of Protagonist Therapeutics stock for Q2 2020, up 267% quarter-over-quarter.
  • 25 funds opened new Protagonist Therapeutics positions in Q2 2020 and 17 closed out, a net change of +8 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2020 was Adage Capital Partners, an estimated $27.6M added.
  • The largest Protagonist Therapeutics seller in Q2 2020 was Sphera Funds Management, an estimated $3.71M sold.

Based on aggregated 13F filings for Q2 2020.